AXQ Capital LP Invests $106,000 in REGENXBIO Inc. (NASDAQ:RGNX)

AXQ Capital LP bought a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 13,732 shares of the biotechnology company’s stock, valued at approximately $106,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in shares of REGENXBIO by 273.1% during the fourth quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC grew its holdings in REGENXBIO by 166.8% during the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares in the last quarter. Teacher Retirement System of Texas increased its stake in REGENXBIO by 19.9% during the 4th quarter. Teacher Retirement System of Texas now owns 12,590 shares of the biotechnology company’s stock worth $97,000 after buying an additional 2,088 shares during the period. Erste Asset Management GmbH acquired a new position in REGENXBIO in the 3rd quarter worth $140,000. Finally, Intech Investment Management LLC purchased a new position in REGENXBIO in the 3rd quarter valued at about $161,000. 88.08% of the stock is owned by institutional investors and hedge funds.

REGENXBIO Stock Performance

NASDAQ RGNX opened at $8.70 on Tuesday. REGENXBIO Inc. has a one year low of $5.62 and a one year high of $22.42. The company has a 50-day simple moving average of $7.34 and a 200-day simple moving average of $8.85. The firm has a market capitalization of $435.75 million, a PE ratio of -1.73 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last issued its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, beating analysts’ consensus estimates of ($1.27) by $0.26. The company had revenue of $21.21 million during the quarter, compared to the consensus estimate of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. Equities analysts forecast that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on RGNX shares. The Goldman Sachs Group cut REGENXBIO from a “buy” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Chardan Capital reaffirmed a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. Raymond James began coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. Royal Bank of Canada restated an “outperform” rating and issued a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. Finally, Morgan Stanley increased their price objective on shares of REGENXBIO from $22.00 to $24.00 and gave the company an “overweight” rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $33.88.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.